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Summary Tamoxifen (tam) is used extensively for treatment of patients with breast cancer and is being evaluated for chemoprevention in
healthy women. It has, however, been reported to increase the risk of endometrial cancer in post-menopausal women, probably by an
oestrogenic effect on the endometrium. It also causes endometrial cysts and polyps. The aims of this study were to identify the incidence of
endometrial thickening, polyps and cysts by transvaginal ultrasound (TVUS) screening of a population of post-menopausal healthy women in
the Royal Marsden tamoxifen chemoprevention trial and to evaluate the possible benefit from the use of intermittent norethisterone (NE) in
women with persistent changes. Since 1990, we have undertaken regular TVUS, using an endovaginal B mode probe, of the 463 post-
menopausal women in the trial randomized to tam (20 mg day-') or placebo (plac), without breaking the randomization code. Endometrial
thickening (ET) was defined as .8 mm at the widest point across the myometrial cavity in the longitudinal plane, including any stromal
changes. Cystic changes were defined as more than one hypoechogenic area > 1 mm. Polyps were identified using saline hydrosonography.
Oral NE (2.5 mg day-1) was used for 21 days out of 28 for three consecutive cycles by women with persistent endometrium .8 mm, including
cystic and polypoid changes. TVUS was repeated after the three courses to evaluate any change caused by NE and endometrial biopsies,
including hysteroscopy, was performed on those women with persistent abnormalities. A persistent ET . 8 mm was identified in 56 (24%) of
the 235 women on tamoxifen compared with only 5 (2%) of 228 women on placebo (P <0.0005). Stromal changes, including cysts, were
detected in 36 (15%) and polyps in 26 (11%) of the women on tamoxifen compared with only two (<1%) of the women on placebo
(P << 0.0005). After 3 months of cyclical norethisterone, 39 of 47 women (83%) on tamoxifen had persistent ultrasound changes. However, 45
(96%) had a progesterone withdrawal bleed. Hysteroscopy was performed in 39 women on tamoxifen (28 endometrial biopsy, 15
polypectomy), five of whom had histological evidence of a proliferative endometrium and a further three had an atypical hyperplastic
endometrium (one of whom had a focus of invasive carcinoma). The cysts and polyps which were detected in women on tam could not be
reversed by NE and were presumably stromal and not of malignant risk. However, 96% of the women had withdrawal NE bleeding, indicating
an oestrogenically primed endometrium which could be a mechanism for an increased risk of endometrial cancer. Further studies are required
to ascertain whether a progestin would protect against this risk. As in other studies, these results indicate that any increased risk of
endometrial cancer caused by tamoxifen is low, and that TVUS screening is probably not justified for asymptomatic women on tamoxifen.
Tamoxifen has been clearly shown to significantly reduce the risk
ofrelapse and improve survival ofpatients with primary operable
breast cancer (Early Breast Cancer Trialists' Collaborative Group,
1992). Furthermore, it will also significantly reduce the risk of
contralateral breast cancer by about 40-50% (Early Breast Cancer
Trialists' Collaborative Group, 1992). Based on these findings, it
is now widely used and many millions of women have had, or are
now receiving, such treatment. Most of these women are healthy,
have a good prognosis and, therefore, the long-term safety of this
treatment is essential.
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Overall, the acute toxicity of tamoxifen is low and its overall
safety is reassuring (Powles, 1992). However, there is concern
about its potential carcinogenic effects in human (Powles and
Hickish, 1995). In rats, tamoxifen is genotoxic, causing DNA
adducts in the liver (Robinson et al, 1991; Han and Liehr, 1992)
associated with the development ofmalignant liver tumours in the
rat, but not other species (White et al, 1992; Phillips et al, 1994).
In humans, there have been no reports of any increased risk of
liver cancers, nor of adducts in liver tissue from women on tamox-
ifen (Martin etal, 1995). There is, however, areported increased risk
of endometrial cancer in post-menopausal women (Fomander et al,
1993) not associated with any adducts in the endometrium
(Carmichael etal, 1996) and indicating anon-genotoxic mechanism.
At 20 mg day-' this increased risk ofendometrial cancer is probably
about two- to threefold (van Leeuwen et al, 1994), which is similar
to the increased riskreported withunopposedoestrogen replacement
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therapy (ERT) associated with endometrial hyperplasia and atypia
(Grady et al, 1995). The ERT changes can be prevented by the
concomitant intermittent administration of a progestin such as
norethisterone (Grady et al, 1995), presumably by causing with-
drawal bleeding of an oestrogenically primed endometrium.
There have been many reports of abnormalities identified in the
endometrium in women on tamoxifen including hyperplasia with
atypia and polyps, some of which are similar to the changes seen
with ERT (Cross and Ismail, 1990; Neven et al, 1990; De Muylder
et al, 1991; Cohen et al, 1993; Lahti et al, 1993; Neven, 1993;
Ismail, 1994; Aleem and Predanic, 1995).
We have previously reported abnormal endometrial cysts,
polyps, hyperplasia and atypia in healthy post-menopausal women
on tamoxifen in our breast cancer chemoprevention trial (Powles
et al, 1990; Kedar et al, 1994). These abnormalities only occurred
in women with an endometrial thickening (ET) of . 8 mm. Since
1990, we have undertaken annual TVUS screening of all post-
menopausal women in our chemoprevention trial and identified 69
women with an ET > 8 mm. The aims ofthis study were to charac-
terize the changes seen in these women, establish their incidence,
and evaluate any effects of intermittent norethisterone.
METHODS
The women in this study were identified from a randomized double-
blind controlled trial of tamoxifen (20 mg daily) vs placebo in
healthy women at increased risk of developing breast cancer
because ofa family history. The details ofthe study design and eligi-
bility criteria have been reported previously (Powles et al, 1989;
Powles et al, 1990; Powles et al, 1994). Since 1990, regular
screening using TVUS of the 463 post-menopausal women in this
trial who have an intact uterus and are not on HRT, has identified 69
asymptomatic women with ET > 8 mm. Post menopausal status was
defined as the cessation of menstrual cycles for at least 12 months.
The clinical characteristics ofthe women are listed in Table 1.
Repeat TVUS was performed on all these women with an
endovaginal B mode probe (Aloka SSD 500, Aloka, Tokyo,
Japan). The ET was measured as the widest point across the cavity
between the endometrial-myometrial interfaces in the longitudinal
plane, including any potentially abnormal stromal tissue. The
appearance of the endometrium was defined as cystic ifthere were
more than one hypoechogenic areas greater than 1 mm in
maximum diameter. Intrauterine polyps were delineated by instil-
lation of intracavity saline (saline hydrosonography) (Bourne et al,
1994). The endometrial layer was defined as polypoidal if there
were any intrauterine protrusions greater than 5 mm in maximum
diameter. Therefore, using TVUS and saline hydrosonography, the
thickened endometrial layer could be classified as non-cystic, non-
polypoidal; non-cystic, polypoidal; cystic, non-polypoidal; and
cystic, polypoidal.
All TVUS examinations were undertaken without breaking the
code for tamoxifen or placebo, and the results were recorded and
stored in the main data base. All analyses were undertaken from
the database without knowledge ofindividual treatment allocation.
Reports were reviewed independent ofthe operator.
Oral norethisterone 2.5 mg was prescribed daily for 21 days out
of28 days for three consecutive cycles to women confirmed with an
ET > 8 mm. Per vaginal withdrawal bleeding following any of the
three cycles were subjectively graded by the participant as: none;
mild, as a scanty 'show' for I day; moderate, as a proper bleed for at
least 2 days; and heavy, with clots. Ultrasonography was repeated at
Table 1 Clinical characteristics
Total number of women in chemoprevention study 2297
Total number of post-menopausal women 843
Total number of post-menopausal women 463
with intact uterus not on HRT
Number of participants with ET > 8 mm 69
Number of participants with repeat ET > 8 mm 61
Number of patients compliant with norethisterone 51
Three courses 50
Two courses 1
Age at entry in norethisterone study, median (range) 57 (46-74)
Years since last menstrual period, median (range) 6 (1-27)
Years on chemoprevention study, median (range) 3 (1-7)
Table 2 Transvaginal ultrasound abnormalities found in 463 post-
menopausal women on tamoxifen 20 mg day- or placebo
Tamoxifen Placebo P-value
Number of patients 235 228
Initial ET > 8 mm 60 (26) 9 (4) < 0.0005
Repeat ET > 8 mm 56 (24) 5 (2) < 0.0005
Ultrasound abnormalities
Non-cystic, non-polypoid 12 (5) 3 (1) Cysts:
Cystic, non-polypoid 18 (8) 1 (< 1) < 0.0005
Non-cystic, polypoid 8 (3) 1 (< 1) Polyps:
Cystic, polypoid 18 (8) 1 (<1) < 0.0005
Cysts are more common in women on tamoxifen vs placebo, P < 0.0005; and
polyps are more common in women on tamoxifen vs placebo, P < 0.0005.
Numbers in parentheses are percentages.
3 months after three courses of norethisterone to document any
change in the TVUS and hydrosonographic appearances.
Endometrial biopsies were taken at the start of the study using a
sterile disposable suction pipelle curette (Unimar, Wilton,
Connecticut) on an outpatient basis. Hysteroscopy, with resection
biopsies and/or dilatation and curettage, was performed if there
was persistent endometrial abnormality on TVUS after 3 months'
intermittent progestin. Tissue fragments were examined under
light microscopy and classified as normal atrophic, proliferative or
hyperplastic endometrium. The presence of atypia, and the
histology ofpolyps, ifpresent, were also recorded.
Statistical methods
The number of patients with persistent TVUS abnormalities was
expressed as a percentage of the total number of patients having
ultrasound tests. Differences between the treatment arms were
assessed by means of a binomial test of proportions. Changes in
TVUS abnormalities after treatment with norethisterone were
assessed in all compliant patients. A comparison ofthe prevalence
of cysts and polyps before and after treatment was done using the
test ofproportions.
RESULTS
An abnormal or thickened ET >8 mm was found on routine
screening using TVUS in 69 (15%) of 463 post-menopausal
women in this tamoxifen chemoprevention trial. These changes
were confirmed on repeat TVUS in 61 participants who were
considered eligible for the norethisterone study. Fifty-four ofthese
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Table 3 Transvaginal ultrasound (TVUS) abnormalities and withdrawal bleeding in 47 women on tamoxifen and four women on placebo before and after
3 months' medication with norethisterone acetate (NA)
Tamoxifen
Pre-NA Post-NA
Placebo
Pre-NA Post-NA
Total number assessable complaint for NA
with ET> 8mm 47 39 (83) 4 3 (75)
TVUS abnormalities
Non-cystic, non-polypoid 11 (23) 13 (28) 2 (50) 2
Cystic, non-polypoid 15 (32) 12 (26) 1 (25) 1
Non-cystic, polypoid 6 (13) 5 (11) 1 (25) 1
Cystic, polypoid 15 (32) 17 (44) 0 0
Withdrawal bleeding
Total 47 4
None 2 1
Light 17 2
Moderate 11 96% 0 75%
Heavy 17 1
No significant changes in the prevalence of cysts or polyps after treatment. Numbers in parentheses are percentages.
women consented to inclusion in the norethisterone trial, but three
women never took the norethisterone tablets (Table 1), leaving 51
women assessable for the norethisterone study.
A persistent ET > 8 mm was identified in 56 (24%) of the 235
women on tamoxifen compared with 5 (2%) ofthe 228 women on
placebo (P < 0.0005) (Table 2). Using saline hydrosonography,
these abnormalities were classified as non-cystic, non-polypoid in
12 (5%) of women on tamoxifen vs 3 (1%) of women on placebo;
cystic, non-polypoid in 18 (8%) tamoxifen vs 1 (< 1%) placebo
women; non-cystic, polypoid in 8 (3%) tamoxifen vs 1 (< 1%)
placebo women; and both cystic and polypoid in 18 (8%) tamox-
ifen vs none in placebo women [women on tamoxifen showed
more cysts (P < 0.0005) and polyps (P < 0.0005)]. This gives a
total of 36 (15%) of 235 women on tamoxifen who had cysts and
26 (11%) who had polyps.
After 3 months of cyclical norethisterone, 39 of the 47 women
on tamoxifen (83%) had persistent abnormalities with no signifi-
cant differences in the prevalence of cyst or polyps (Table 3).
However, 96% of the 47 women on tamoxifen experienced with-
drawal bleeding with norethisterone, in spite oflittle change being
seen on the TVUS (Table 3).
Initial specimens obtained by suction pipelle curette were found
to be inadequate for either histological or cytological analysis in
33 out of42 samples. As a consequence, this method was not used
for the remaining nine participants.
Hysteroscopy was performed in the 42 women with persistent
abnormalities on TVUS after norethisterone (Table 4). Thirty-nine
of these women were tamoxifen participants, 28 of whom had an
endometrial biopsy and 15 underwent polypectomy. An inade-
quate sample associated with an atrophic endometrium was diag-
nosed in 19 women, with only five women having a proliferative
endometrium, and a further four having a hyperplastic endo-
metrium with atypia. One of these women was found to have a
small focus ofendometrial cancer at hysterectomy.
There was no evidence of histological atypia or abnormal
mitosis in the 15 polypectomy specimens. Ofall these participants,
six women had both endometrial and polypoidal specimens. One
woman had atypical changes in the endometrial tissue, but not in
Table 4 Histological findings in 42 women having persistent TVUS
abnormalities after 3 months of norethisterone
Tamoxifen Placebo
Hysteroscopy 39 3
Endometrial biopsy 28 2
Inadequate sample/atrophic 19 2
Proliferative 5 0
Hyperplastic with atypia 4 0
Polypectomy
Simple polyp 12 0
Hyperplastic 3 0
the polypoidal tissue; one woman had proliferative changes in the
endometrial tissue, with hyperplastic changes in the polypoidal
tissue; and four women had no proliferative or atypical changes in
the endometrial and polypoidal tissue. None of the three women
on placebo had proliferative or atypical changes.
DISCUSSION
Many of the previous data relating to the ultrasound and patho-
logical endometrial changes which occur with tamoxifen has been
based on anecdotal unblinded observations in patients treated for
breast cancer. In this study, we have had the opportunity to eval-
uate these abnormalities in a population of healthy women on
tamoxifen, or placebo, in a chemoprevention trial.
We have found that 26% of women on tamoxifen have an
ET 2 8 mm. Using hydrosonography, it is possible to identify in
these women with endometrial thickening, cysts in 7%, polyps in
3% and both cysts and polyps in 8% of women on tamoxifen.
These changes are quite characteristic of tamoxifen and quite
unlike those seen with ERT. Hysteroscopic examination often
reveals tough, fibrous changes, which are presumably stromal, and
not necessarily associated with endometrial hyperplasia. Colour
Doppler, to evaluate subendometrial blood flow, would be helpful
to elucidate this.
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The cystic and polypoid abnormalities remained unaffected by
norethisterone. However, an increased risk of sarcoma of the
uterus has not been associated with tamoxifen, and any stromal
abnormalities are unlikely to be related to an increased risk of
endometrial cancer. Of relevant interest was the observation that
most tamoxifen women (96%) had evidence of withdrawal
bleeding with norethisterone, indicating an oestrogenically primed
endometrium, presumably caused by tamoxifen. This would
suggest that any malignant risk associated with an oestrogenic
effect of tamoxifen on the endometrium should be preventable by
norethisterone as with ERT.
Finally, from this small screening study, the risk of endometrial
cancer in post-menopausal women on tamoxifen would appear to
be low. With regard to endometrial cancer, this small study does
not adequately assess the risk caused by tamoxifen, principally
because histology was only obtained after 3 months norethisterone
medication. Nonetheless, since the start of the chemoprevention
trial in 1986, only two women on tamoxifen had developed
endometrial cancer by 1990 when the TVUS screening
programme started. Since then, only one further endometrial
cancer has occurred and was detected in the programme involving
over 1000 TVUS examinations. During this time there have been
28 breast cancers in the 843 post-menopausal women on tamox-
ifen or placebo. In conclusion, although the actual number of
patients evaluated in this study is small, and the observer error is
significant, the results indicate that TVUS screening is probably
notjustified for women on adjuvant tamoxifen or in chemopreven-
tion trials, and that any increased risk of endometrial cancer is
sufficiently low not to warrant the development of norethisterone
as a preventative strategy. Early detection ofendometrial cancer in
women on tamoxifen should depend on diligent gynaecological
assessment for women who develop symptoms, especially post-
menopausal bleeding.
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